Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6785283 | 0.90 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1CYP1A2POLBHPGD | |
| SCHEMBL6787352 | 0.89 | ALDH1A1 (0.55) | ALDH1A1L3MBTL1CYP1A2POLBHPGD | |
| SCHEMBL6785344 | 0.85 | ALDH1A1 (0.67) | ALDH1A1L3MBTL1CYP1A2POLBHPGD | |
| SCHEMBL5569592 | 0.82 | POLB (0.53) | ALDH1A1L3MBTL1CYP1A2POLBGAA | |
| Hydrochloric Acid SCHEMBL5570630 | 0.81 | POLB (0.52) | ALDH1A1L3MBTL1CYP1A2POLBGAA | |
| SCHEMBL4640409 | 0.78 | LMNA (0.59) | GAALMNAHTTSMN1; SMN2 | |
| SCHEMBL27535462 | 0.77 | POLB (0.74) | ALDH1A1L3MBTL1CYP1A2POLBGAA | |
| SCHEMBL10334481 | 0.77 | POLB (0.84) | ALDH1A1L3MBTL1CYP1A2POLBGAA | |
| SCHEMBL6788134 | 0.77 | RAB9A (0.51) | ALDH1A1L3MBTL1CYP1A2POLBGAA | |
| SCHEMBL19657233 | 0.76 | ALOX15 (0.68) | ALDH1A1L3MBTL1POLBHPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6828316-B2 | Antiallergens | KOWA CO., LTD. (JP) | 2004-12-07 | — | — | US | disclosed |
| US-20020042414-A1 | Diamide compound and medicine containing the same | KOWA CO., LTD. (JP) | 2002-04-11 | — | — | US | disclosed |
| US-6340682-B1 | FOR THERAPY OF ALLERGIC IMMUNOLOGICAL DISEASE IS SELECTED FROM ASTHMA, ALLERGIC RHINITIS, INFLAMMATORY LARGE BOWEL DISEASE OR CONTACT DERMATITIS | KOWA CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-0926138-A1 | DIAMIDE COMPOUNDS AND DRUGS CONTAINING THE SAME | KOWA CO. LTD. (JP) | 1999-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042414-A1 | Diamide compound and medicine containing the same | HRH4, HRH2, HRH1 | ALDH1A1 836/4885L3MBTL1 3376/4885CYP1A2 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.